Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions

NCT ID: NCT04547998

Last Updated: 2024-05-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-10
• Study Completion Date: 2023-01-31

Brief Summary

This is a prospective blinded within-subject randomized study to evaluate the application of Spray-On Skin™ Cells, prepared using the RECELL® Device for safe and effective repigmentation of ablated stable vitiligo lesions.

Conditions

Vitiligo

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

All Participants (within patient control)

Each participant will serve as their own Control, receiving both Control and Investigational Interventions randomly allocated to treatment of a portion of a depigmented vitiligo lesion.

Group Type: EXPERIMENTAL

Control Intervention (UVB)

Intervention Type: DEVICE

Targeted narrowband-UVB phototherapy in alignment with published Vitiligo Working Group recommendations.

Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)

Intervention Type: DEVICE

Spray-On Skin™ Cells prepared using RECELL will be applied to an area prepared by ablative laser, followed by targeted narrowband UVB phototherapy.

Interventions

Control Intervention (UVB)

Targeted narrowband-UVB phototherapy in alignment with published Vitiligo Working Group recommendations.

Intervention Type: DEVICE

Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)

Spray-On Skin™ Cells prepared using RECELL will be applied to an area prepared by ablative laser, followed by targeted narrowband UVB phototherapy.

Intervention Type: DEVICE

Other Intervention Names

Phototherapy

Eligibility Criteria

Inclusion Criteria

1. Focal, segmental or generalized (i.e., nonsegmental) stable vitiligo, defined as no new depigmented areas nor any depigmented areas that have expanded in size within the preceding 12 months, regardless of whether the areas are intended to be used as study areas.

1a. Photo documentation (current and at least 12 months prior) of the patient's depigmented areas have been evaluated as stable by an independent Screening Committee.

2. The patient has not undergone topical treatment (e.g., steroids, tacrolimus) for the study areas within the past 90 days.

3. The patient has not undergone phototherapy (e.g., NB-UVB) for the study areas within the past 90 days.

4. The patient is a candidate for surgical intervention of a depigmented area, defined as a patient who has previously been compliant with but has not satisfactorily responded to both

a. topical therapy and b. a minimum of 3 months of phototherapy.

5. The patient must have two study areas available for treatment that:

1. are of similar size (±50%),

2. are between 16cm2 and 456cm2 (contiguous),

3. are similarly sun exposed,

4. have the same extent of leukotrichia, and

5. are judged clinically as ≥90% depigmented (by area).

6. The patient is 18 years of age or older.

7. The patient is willing and able to comply with post-treatment at-home phototherapy and all follow-up evaluations required by the study protocol.

8. The patient agrees to abstain from any other treatment of the study areas for the duration of his/her participation in the study (52 weeks).

9. The patient agrees to abstain from enrollment in any other interventional clinical trial for the duration of his/her participation in the study (52 weeks).

10. In the opinion of the investigator, the patient must be able to:

a. Understand the full nature and purpose of the study, including possible risks and adverse events, b. Understand instructions, and c. Provide voluntary written informed consent.

Exclusion Criteria

1. The study areas selected have concomitant dermatologic conditions other than vitiligo.

2. The study area selected for treatment includes the lips, eyelids, plantar surface of feet, palmar surface of hands, fingertips, wrists, ankles, elbows, or knees.

3. The patient is unable to undergo the treatment area preparation.

4. Patients who are pregnant.

5. Patients with:

1. universalis vitiligo,

2. depigmented areas over >30% of their body surface area,

3. depigmented lips and fingertips (lip-tip vitiligo), or

4. > 3 depigmented fingertips, defined as depigmentation of the dorsal aspect of the fingertip from the distal interphalangeal joint to the tip of the digit.

6. Patients with recent history (within previous 12 months) of:

1. Koebnerization,

2. confetti-like, or

3. trichrome lesions.

7. Patients with a history of keloid formation.

8. Patients who have used a tanning salon in the past 60 days.

9. The patient has other concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives.

10. Current use of medications (e.g., anticoagulants such as heparin or warfarin) that in the investigator's opinion may compromise patient safety or trial objectives.

11. The patient has a known hypersensitivity to trypsin or compound sodium lactate for irrigation (Hartmann's) solution.

12. Life expectancy is less than 1 year.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Avita Medical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

University of California, Irvine

Irvine, California, United States

University of California, Davis

Sacramento, California, United States

West Dermatology

San Diego, California, United States

DMR Research

Westport, Connecticut, United States

Skin Care Research, LLC

Hollywood, Florida, United States

Miami Dermatology and Laser Institute

Miami, Florida, United States

University of Massachusetts

Worcester, Massachusetts, United States

Henry Ford Health System

Detroit, Michigan, United States

Dermatology, Laser & Vein Specialists of the Carolinas

Charlotte, North Carolina, United States

Medical University of South Carolina

Charleston, South Carolina, United States

University of Texas at Austin Dell Medical School

Austin, Texas, United States

Heights Dermatology

Houston, Texas, United States

Countries

United States

References

Liu JP, Hsueh HM, Hsieh E, Chen JJ. Tests for equivalence or non-inferiority for paired binary data. Stat Med. 2002 Jan 30;21(2):231-45. doi: 10.1002/sim.1012.

Reference Type: BACKGROUND

PMID: 11782062 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

CTP009

Identifier Type: -

Identifier Source: org_study_id